What purpose is Mounjaro prescribed for in the UK?

What the licensing data established about Mounjaro's intended purpose

The SURMOUNT clinical programme was built to answer a specific question: can tirzepatide produce meaningful, sustained weight reduction in adults with obesity? SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight plus at least one weight-related condition (excluding diabetes) and followed them for 72 weeks. At the 15 mg dose, average body-weight reduction reached around 20–21%, a figure that exceeded anything previously seen from a single weekly injection in a trial of that scale.

That evidence base directly underpinned the UK licence. The Medicines and Healthcare products Regulatory Agency approved Mounjaro for weight management alongside a reduced-calorie diet and increased activity, for adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present, conditions such as high blood pressure, obstructive sleep apnoea, dyslipidaemia, or type 2 diabetes. The parallel licence for type 2 diabetes rests on a separate programme, the SURPASS trials, which demonstrated meaningful reductions in HbA1c as well as body weight.

A question our prescribers hear most weeks is whether Mounjaro is "a diabetes drug" or "a weight-loss drug". The honest answer is both: it carries separate, distinct licences for each purpose, and the prescriber's job is to determine which applies (or whether both are relevant) for a given patient.

How tirzepatide's dual-receptor action shapes what it does

Most GLP-1 medicines activate a single receptor pathway. Tirzepatide activates two: the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both are involved in regulating appetite, slowing the rate at which the stomach empties, and moderating blood-sugar responses after meals. Triggering both pathways simultaneously appears to produce a stronger appetite-suppressing effect than activating either alone, which is the most widely cited explanation for why the trial results looked different from earlier medicines in the class.

This mechanism is why Mounjaro is described as a dual agonist, and why the NHS tirzepatide page is careful to distinguish it from semaglutide-based treatments. The practical effect, in clinical trial participants, was that appetite fell substantially, food intake reduced, and body weight followed. Whether that translates to a specific outcome for any individual depends on factors a prescriber weighs at assessment, biology, existing conditions, other medicines, and realistic expectations.

Treatment starts at the 2.5 mg dose, which exists to let the body adjust rather than to produce therapeutic weight loss immediately. The prescriber then titrates upward, typically in four-week steps, to the dose that is both effective and well tolerated. If you want to understand the full range of what the medicine can cause (including common side effects) the Mounjaro side effects page covers that in detail.

Who qualifies, and what NICE says about access on the NHS

NICE recommended tirzepatide for use in England in December 2024 (Technology Appraisal 1026), with updated guidance from September 2025. The NHS is rolling out access in phases: from June 2025, adults with a BMI of 40 or above and four or more specific weight-related conditions qualify first. The BMI threshold applies 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Cohort 2, covering BMI 35–39.9 with four or more conditions, activated in June 2026. Each phase adds more patients, but NHS availability still varies considerably by area.

Private prescribing follows the licensed eligibility criteria directly: BMI 30 or above, or 27 or above with a qualifying weight-related condition. At nume, every application goes through a same-day clinical review by a GPhC-registered Independent Prescriber, a real clinician reads your consultation responses, not an automated system. If you are already on treatment elsewhere and considering switching, the page on what Mounjaro is used for has more on how transfer patients are assessed. The Mounjaro price comparison page is worth reading if cost is a factor in your decision, since private pricing has shifted considerably since Eli Lilly adjusted UK list prices in September 2025.

Mounjaro is not licensed for use in people under 18, and it is not recommended during pregnancy, while breastfeeding, or when trying to conceive. These exclusions are part of the clinical assessment every patient goes through before a prescription is issued.

What Mounjaro is not licensed for, a brief but important distinction

Because tirzepatide is also sold under different names in other countries, a few misconceptions circulate online. Tirzepatide sourced for research purposes is not the same product, is not subject to pharmaceutical manufacturing controls, and has no place in clinical weight management. The US brand name Zepbound does not exist as a UK product; in the UK, tirzepatide for weight management is Mounjaro, full stop.

Ozempic, which contains semaglutide, is licensed in the UK for type 2 diabetes, not weight loss, the MHRA's position on this is unambiguous. People searching for weight-loss treatment who land on Ozempic content are being pointed at the wrong licence. If you want a broader look at how tirzepatide sits within the range of weight-management options, the weight-loss treatments overview maps out what is actually available. The Mounjaro overview page and the tirzepatide information page go deeper on mechanism and background if you want more detail before speaking to a prescriber.

If you have read enough and want a clinical assessment, our prescribers are available the same day. Start your free consultation to find out whether Mounjaro is the right fit for you.